BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
acalabrutinib Resistant: A2 - Guideline
|
acalabrutinib Resistant: A2 - Guideline
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
LOXO-305 Sensitive: C3 – Early Trials
|
LOXO-305 Sensitive: C3 – Early Trials
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
ibrutinib Resistant: C3 – Early Trials
|
ibrutinib Resistant: C3 – Early Trials
|
BTK C481S
|
Mantle Cell Lymphoma
|
BTK C481S
|
Mantle Cell Lymphoma
|
TG-1701 Sensitive: D – Preclinical
|
TG-1701 Sensitive: D – Preclinical
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
GS-9973 Sensitive: D – Preclinical
|
GS-9973 Sensitive: D – Preclinical
|
BTK C481S
|
Mantle Cell Lymphoma
|
BTK C481S
|
Mantle Cell Lymphoma
|
ibrutinib Resistant: D – Preclinical
|
ibrutinib Resistant: D – Preclinical
|
BTK C481S
|
Mantle Cell Lymphoma
|
BTK C481S
|
Mantle Cell Lymphoma
|
SRX3262 Sensitive: D – Preclinical
|
SRX3262 Sensitive: D – Preclinical
|
BTK C481S
|
CLL
|
BTK C481S
|
CLL
|
SNS-062 Sensitive: D – Preclinical
|
SNS-062 Sensitive: D – Preclinical
|